Module

New Drugs for Treatment-Experienced Patients

Source: HIV/AIDS Annual Update 2006

New Drugs for Treatment-Experienced Patients

CME Program Director: John P. Phair, MD

Faculty:
Kimberly Y. Smith, MD, MPH

CME CREDIT INFORMATION

Release Date: 06/30/06

Expiration Date: 06/29/07

Physicians: maximum of 1.5 AMA PRA Category 1 Credit(s)™

Pharmacists: 1.5 contact hours (0.15 CEUs)

Registered Nurses: 1.9 Nursing CE credits

Status: Please log in to view status

Learning Objectives

Upon completion of this activity, participants should be able to:

Identify investigational agents from existing and novel antiretroviral classes in current clinical development for use in treatment-experienced patients
Discuss results from phase II and III studies of new antiretrovirals in treatment-experienced patients
Describe current clinical strategies for control of HIV disease in treatment-experienced patients

Topics covered include:

Introduction
PIs: Tipranavir
PIs: Darunavir (TMC114)
PIs: Brecanavir (GW640385)
NNRTIs: Etravirine (TMC125)
NNRTIs: TMC278
NRTIs
Integrase Inhibitors: Introduction
Integrase Inhibitors: MK-0518
Integrase Inhibitors: GS-9137
Maturation Inhibitors: PA-457
Conclusions
Summary: Implications for Clinical Practice

Disclaimer: The materials published on the Clinical Care Options Web site reflect the views of the reviewers or authors of the CCO material, not those of Clinical Care Options, LLC, the CME provider, or the companies providing educational grants. The materials may discuss uses and dosages for therapeutic products that have not been approved by the United States Food and Drug Administration. A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or using any therapies described in these materials.